Level of galectin-3 and ST2 in ischemic chronic heart failure depending on the functional state of kidneys
DOI:
https://doi.org/10.14739/2310-1210.2014.6.35653Keywords:
Heart Failure, Markers of Fibrosis, Kidney FunctionAbstract
Aim. The aim of the study was to investigate the characteristics of level markers of fibrosis galectin-3 (Gal-3), ST2 in patients with ischemic chronic heart failure (CHF) depending on the glomerular filtration rate.
Methods and results. The study involved 113 patients with ischemic CHF. Depending on glomerular filtration patients were divided into 3 groups: those with normal function (≥90 ml/min/1.73 m2), mild (60-89 ml/min/1.73 m2) and moderate (30-59 ml/min/1.73 m2) kidney dysfunction. It is established that in patients with ischemic CHF with moderate renal dysfunction level of Gal-3 is higher as compared with mild dysfunction and normal renal function (7.1 % and 53.6 %, respectively). The level of ST2 had about the same value in the groups of moderate and mild dysfunction, but was higher than in the group of normal renal function (11.7 % and 12.1 %, respectively). In the group of patients with ischemic CHF with moderate renal dysfunction correlation analysis showing that only Gal-3 revealed interrelationships of NT-proBNP (r=0,77; p=0,04), cystatin C (r=0,91; p=0.002).
Conclusion. In patients with ischemic CHF with normal renal function revealed a strong correlation interrelationships between Gal-3, ST2 and the parameters of the structural remodeling of the left ventricle.
References
Metra, M., Cotter, G., Gheorghiade, M., Dei Cas, L., & Voors, A. (2012). The role of the kidney in heart failure. European Heart Journal, 33(17), 2135–2142. doi:10.1093/eurheartj/ehs205.
Sahasranam, K. (2014). Cardio Renal Syndrome. BMH Medical Journal, 1(4), 72-76.
Lashkul, D. A. (2014). Poshyrenist i koreliatsiino-statustuchni vzaiemozviazky dysfunkcii nurok u khvorykh na khronichnu sertsevu nedostatnist ishemichnoho henesu [Prevalence, correlative and statistical relationships of renal dysfunction in chronic ischemic heart failure patients]. Zaporozhskij medicinskij zhurnal, 1, 26–29 [in Ukrainian].
Okamura, D., Pasichnyk, K., Lopez-Guisa, J., Collins, S., Hsu, D., Liu, F., & Eddy, A. (2011). Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. American Journal Of Physiology-Renal Physiology, 300(1), 245–253. doi: 10.1152/ajprenal.00326.2010.
Ahmad, T., Fiuzat, M., Neely, B., Neely, M., Pencina, M., & Kraus, W. et al. (2014). Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. JACC: Heart Failure, 2(3), 260–268. doi: 10.1016/j.jchf.2013.12.004.
O’Seaghdha, C., Hwang, S., Ho, J., Vasan, R., Levy, D., & Fox, C. (2013). Elevated galectin-3 precedes the development of CKD. Journal Of The American Society Of Nephrology, 24, 1470–1477. doi: 10.1681/ASN.2012090909.
Voronkov, L. G., Amosova, K. M., Bahrii, A. E., Dziak, G. V., Diadyk, O. I., Zharinov, O. Y., et al. (2012) Rekomendatsii z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti [Guidelines for the diagnosis and treatment of chronic heart failure]. Sertseva nedostatnist; 3, 60–96 [in Ukrainian].
(2013) Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international. Suppl, 3, 1–150.
Lassus, J., Nieminen, M., Peuhkurinen, K., Pulkki, K., Siirila-Waris, K., Sund, R., & Harjola, V. (2010). Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. European Heart Journal, 31(22), 2791–2798. doi: 10.1093/eurheartj/ehq293.
Syvolap, V. V., Tumanska, N. V., Popovych, A. O., & Polischuk, L. M. (2012). Rіven tsystatynu C ta NT-pro-BNP u khvorykh na khronіchnu sertsevu nedostatnіst zalezhno vіd vnutrіshnomіokardіalnoho napruzhennia lіvoho shlunochka [Dependence of Cystatin C and NT-pro-BNP levels on intramyocardial tension of the left ventricle in patients with chronic heart failure]. Patolohia, (26), 68–70 [in Ukrainian].
Ueland, T., Aukrust, P., Broch, K., et al. (2011).Galectin-3 in heart failure: high levels are associated with allcause mortality. Int J Cardiol, 150, 361–364.
Weinberg, E., Shimpo, M., Hurwitz, S., Tominaga, S., Rouleau, J., & Lee, R. (2003). Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation, 107(5), 721–726. doi: 10.1161/01.CIR.0000047274.66749.FE.
Bartunek, J., Delrue, L., Van Durme, F., Muller, O., Casselman, F., & De Wiest, B., et al. (2008). Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. Journal Of The American College Of Cardiology, 52(25), 2166–2174. doi: 10.1016/j.jacc.2008.09.027.
Stehouwer, C., Fischer, H., Van Kuijk, A., Polak, B., & Donker, A. (1995). Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes, 44(5), 561–564. doi: 10.2337/diab.44.5.561.
Maurer, G., Huber, K., Wojta, J., Lemberger, C., de Martin, R., & Heinemann, A., et al. (2011). Interleukin-33 Induces Expression of Adhesion Molecules and Inflammatory. Arterioscler Thromb Vasc Biol, 31, 2080–2089. doi: 10.1161/ATVBAHA.111.231431.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
